Adam Cutler
Mamaroneck,NY
Summary
Accomplished biotechnology executive with over 25 years of experience in corporate finance, investor relations, business development, and strategic planning. Exceptional ability to raise capital and enhance investor awareness has consistently driven value for life sciences companies. Renowned for cultivating deep relationships within the biotech and pharmaceutical industries, as well as with institutional investors and equity research analysts. Focused on advancing innovative therapies that benefit patients while maximizing value creation through strategic initiatives.
Overview
29
29
years of professional experience
Work History
Chief Financial Officer
Mural Oncology, Inc.
Waltham, MA
10.2023 - Current
- Guiding company through exploration of strategic alternatives following negative results of late-stage clinical trials
- Joined at spin-off to build finance capability, shape corporate strategy, and raise investor profile.
- Led over 100 investor meetings in 2024 to prepare for upcoming data readouts and financings.
- Secured equity research coverage from four banks without conducting a financing.
- Participated in major healthcare conferences (e.g., Cowen, Jefferies, BofA, Piper, HCW).
- Developed valuation framework with investment bank for use in potential partnership/M&A discussions.
- Coordinated financing strategies across a range of potential data outcomes.
- Reduced real estate expenses through successful subleases; drove operational efficiencies.
Chief Financial Officer
Q32 Bio, Inc.
Waltham, MA
07.2021 - 10.2023
- Led investor outreach and explored multiple financing strategies (crossover, SPAC, reverse merger).
- Negotiated successful reverse merger and PIPE financing with Homology Medicines.
- Contributed to Phase 2 IL-7 antibody collaboration and option deal with Horizon Therapeutics.
- Secured Series C term sheet from new lead investor (round delayed in favor of BD deal).
- Instituted policies enhancing budgeting, forecasting, and public company readiness.
- Negotiated favorable debt amendments and refinanced outstanding obligations.
Chief Financial Officer
Molecular Templates, Inc.
New York, NY
11.2017 - 06.2021
- Raised ~$300M through multiple equity and debt financings.
- Built and managed finance, HR, legal, and IT teams during rapid growth (30 to 250+ employees).
- Led investor relations initiatives, increasing institutional engagement and shareholder base.
- Secured equity research coverage from BofA, Evercore, Stifel, Barclays, Cowen, Jefferies, Oppenheimer, Laidlaw
- Advised on business development deals with BMS, Vertex, and Takeda.
- Partnered with exec team, Board of Directors on strategy and capital planning.
Senior Vice President, Corporate Affairs
Arbutus Biopharma
Vancouver, BC
03.2015 - 11.2017
- Designed and executed IR strategy, leveraging extensive industry network.
- Supported C-suite in business development deal structuring and execution.
- Managed SEC filings and participated in audit committee responsibilities.
- Acted as primary liaison to investors, analysts, and media.
Managing Director
The Trout Group LLC / Trout Capital LLC
New York, NY
06.2012 - 02.2015
- Advised public and private life sciences firms on investor relations and capital markets.
- Facilitated introductions to institutional investors, analysts, and bankers.
- Executed financing transactions and led firm-wide business development efforts.
Director and Senior Biotechnology Analyst
Credit Suisse
New York, NY
04.2011 - 06.2012
- Led equity research coverage for small- and mid-cap biotech companies.
Managing Director and Senior Biotechnology Analyst
Canaccord Genuity
New York, NY
08.2007 - 04.2011
- Ranked among top internal analysts; multiple 'Call of the Month' recognitions.
Director and Senior Biotechnology Analyst
JMP Securities, LLC
New York, NY
04.2004 - 08.2007
- Initiated and maintained broad biotech equity research coverage.
Associate Analyst, Biotechnology Equity Research
Bank of America Securities
New York, NY
11.2000 - 04.2004
Analyst (Life Sciences Strategy, Market Assessments)
The Frankel Group, Inc.
New York, NY
08.1998 - 11.2000
Consultant (Hospital, Healthcare System, Payor Clients)
Ernst & Young LLP, Healthcare Consulting
Boston, MA
06.1996 - 08.1998
Education
B.A. - Economics
Brandeis University
Waltham, MASkills
- Strategic Finance
- Capital Markets
- Investor Relations
- Biotech Fundraising
- Business Development
- M&A
- Public Company Readiness
- Board Leadership
- Audit Committee Leadership
Additional Information
Winner, Wall Street Journal 'Best on the Street' for Biotechnology (2011), NYC Marathon Finisher (2016), Completed single-day Grand Canyon Rim-to-Rim hike (2021, 2023), Occasional half-marathon runner
Board Experience
- InMed Pharmaceuticals, Inc., Vancouver, BC, Board Member; Chair, Audit Committee, 01/01/15, 12/31/22
- Navidea Biopharmaceuticals, Inc., Dublin, OH, Board Member; Chair, Audit Committee, 01/01/18, 12/31/21
Affiliations
InMed Pharmaceuticals, Inc. — Vancouver, BC
Board Member; Chair, Audit Committee
2015–2022
Navidea Biopharmaceuticals, Inc. — Dublin, OH
Board Member; Chair, Audit Committee
2018–2021
Accomplishments
- Winner, Wall Street Journal "Best on the Street" for Biotechnology (2011)
- NYC Marathon Finisher (2016)
- Completed single-day Grand Canyon Rim-to-Rim hike (2021, 2023)
- Occasional half-marathon runner
Timeline
Chief Financial Officer
Mural Oncology, Inc.
10.2023 - Current
Chief Financial Officer
Q32 Bio, Inc.
07.2021 - 10.2023
Chief Financial Officer
Molecular Templates, Inc.
11.2017 - 06.2021
Senior Vice President, Corporate Affairs
Arbutus Biopharma
03.2015 - 11.2017
Managing Director
The Trout Group LLC / Trout Capital LLC
06.2012 - 02.2015
Director and Senior Biotechnology Analyst
Credit Suisse
04.2011 - 06.2012
Managing Director and Senior Biotechnology Analyst
Canaccord Genuity
08.2007 - 04.2011
Director and Senior Biotechnology Analyst
JMP Securities, LLC
04.2004 - 08.2007
Associate Analyst, Biotechnology Equity Research
Bank of America Securities
11.2000 - 04.2004
Analyst (Life Sciences Strategy, Market Assessments)
The Frankel Group, Inc.
08.1998 - 11.2000
Consultant (Hospital, Healthcare System, Payor Clients)
Ernst & Young LLP, Healthcare Consulting
06.1996 - 08.1998
B.A. - Economics
Brandeis University
Similar Profiles
Faith DialFaith Dial
LEAD ENGINEER I at Mural Oncology/Alkermes, Inc.LEAD ENGINEER I at Mural Oncology/Alkermes, Inc.
Michelle JosephMichelle Joseph
Director, Clinical Data Management at Alkermes Inc / Mural Oncology IncDirector, Clinical Data Management at Alkermes Inc / Mural Oncology Inc
Ankita PatelAnkita Patel
Senior Software Engineering Manager at MURALSenior Software Engineering Manager at MURAL